|
 |
|||||||
 |
PRESS RELEASES ADVENTRX Pharmaceuticals Completes Move to New Facility SAN DIEGO – July 22, 2004 – -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it relocated to a new facility in the Sorrento Mesa area of San Diego and that its administrative functions are fully operational at this site. The move took place as scheduled. "I am pleased that the move was executed as planned and with minimal interruption. The larger, refurbished space accommodates new staffing and will allow us to increase the scope and progress of our clinical and product development programs. Final upgrades to the three laboratories in this facility are underway," said Nicholas Jon Virca, ADVENTRX Pharmaceuticals' President and CEO. The Company's new address is 6725 Mesa Ridge Road, Suite 100, San Diego, CA 92121. New phone and fax numbers are (858) 552-0866 and (858) 552-0876, respectively. Driving directions to the new facility can be found on the Company's website at www.adventrx.com/contact/directions.htm. About ADVENTRX ADVENTRX Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contact: The Ruth Group Investors: Stephanie Carrington 646-536-7017 Media: Cynthia Isaac, Ph.D. 646-536-7028 |
